Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha

Joint Bone Spine

Volumn 84, Issue 4, 2017, Pages 441-445

  Mabille, Charlotte ^a   Degboe, Yannick ^a   Constantin, Arnaud ^a   Barnetche, Thomas ^b   Cantagrel, Alain ^a   Ruyssen Witrand, Adeline ^a  

^a CHU PURPAN   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Anti TNF ; Infection; Rheumatoid arthritis; Surgery

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ARTICLE; HUMAN; INFECTION RISK; ORTHOPEDIC SURGERY; POSTOPERATIVE INFECTION; RHEUMATOID ARTHRITIS; SURGICAL INFECTION; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; INFECTION; META ANALYSIS; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INFECTION; ORTHOPEDIC PROCEDURES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84994765054     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2016.06.011     Document Type: Article

References (23)

1. Luessenhop, C.P., Higgins, L.D., Brause, B.D., et al. Multiple prosthetic infections after total joint arthroplasty. Risk factor analysis. J Arthroplasty 11 (1996), 862–868.
2. Scanzello, C.R., Figgie, M.P., Nestor, B.J., et al. Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J 2 (2006), 141–147.
3. Krause, M.L., Matteson, E.L., Perioperative management of the patient with rheumatoid arthritis. World J Orthop 5 (2014), 283–291.
4. Goeb, V., Ardizzone, M., Arnaud, L., et al. Recommendations for using TNFalpha antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. Joint Bone Spine 80 (2013), 574–581.
5. Saag, K.G., Teng, G.G., Patkar, N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59 (2008), 762–784.
6. Scherrer, C.B., Mannion, A.F., Kyburz, D., et al. Infection risk after orthopaedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs. Arthritis Care Res (Hoboken) 65 (2013), 2032–2040.
7. Momohara, S., Kawakami, K., Iwamoto, T., et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 21 (2011), 469–475.
8. Kawakami, K., Ikari, K., Kawamura, K., et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications?. Rheumatology (Oxford) 49 (2010), 341–347.
9. Giles, J.T., Bartlett, S.J., Gelber, A.C., et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopaedic infection in rheumatoid arthritis. Arthritis Rheum 55 (2006), 333–337.
10. Suzuki, M., Nishida, K., Soen, S., et al. Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. J Orthop Sci 16 (2011), 778–784.
11. Kubota, A., Nakamura, T., Miyazaki, Y., et al. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 22 (2012), 844–848.
12. Johnson, B.K., Goodman, S.M., Alexiades, M.M., et al. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol 40 (2013), 617–623.
13. Bongartz, T., Halligan, C.S., Osmon, D.R., et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 59 (2008), 1713–1720.
14. den Broeder, A.A., Creemers, M.C., Fransen, J., et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34 (2007), 689–695.
15. Hirano, Y., Kojima, T., Kanayama, Y., et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 29 (2010), 495–500.
16. Berthold, E., Geborek, P., Gulfe, A., Continuation of TNFa blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopaedic and hand surgery procedures. Acta Orthop 84 (2013), 495–501.
17. Bibbo, C., Goldberg, J.W., Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25 (2004), 331–335.
18. Ruyssen-Witrand, A., Gossec, L., Salliot, C., et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 25 (2007), 430–436.
19. Talwalkar, S.C., Grennan, D.M., Gray, J., et al. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 64 (2005), 650–651.
20. Wendling, D., Surgery in rheumatoid arthritis patients under anti-TNF-alpha therapy: what is the risk?. Clin Rheumatol 26 (2007), 1396–1397.
21. Goodman, S.M., Menon, I., Christos, P.J., et al. Management of perioperative tumour necrosis factor alpha inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology (Oxford) 55 (2016), 573–582.
22. Doran, M.F., Crowson, C.S., Pond, G.R., et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46 (2002), 2294–2300.
23. Mangram, A.J., Horan, T.C., Pearson, M.L., et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20 (1999), 250–278 quiz 79-80.